NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastases

Lancet Oncol. 2016 Mar;17(3):275-6. doi: 10.1016/S1470-2045(16)00060-7. Epub 2016 Jan 27.

Authors

Nwamaka Umeweni¹, Helen Knight², Gary McVeigh²

Affiliations

¹ National Institute for Health and Care Excellence, Manchester M1 4BT, UK. Electronic address: [email protected].
² National Institute for Health and Care Excellence, Manchester M1 4BT, UK.

PMID: 26827242
DOI: 10.1016/S1470-2045(16)00060-7

No abstract available

Publication types

News

MeSH terms

Aged
Bone Neoplasms / mortality
Bone Neoplasms / secondary*
Bone Neoplasms / therapy*
Disease-Free Survival
Humans
Male
Middle Aged
Neoplasm Recurrence, Local / mortality
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / therapy
Practice Guidelines as Topic*
Prognosis
Prostatic Neoplasms, Castration-Resistant / mortality
Prostatic Neoplasms, Castration-Resistant / pathology*
Prostatic Neoplasms, Castration-Resistant / therapy*
Radioisotopes
Radium*
Risk Assessment
Survival Rate
Treatment Outcome
United Kingdom

Substances

Radioisotopes
radium Ra 223 dichloride
Radium